Here's what Ozempic and Wegovy are really doing to your mouth
'Ozempic face' is another commonly reported consequence of using these popular weight loss drugs.
This is a sunken or hollowed-out appearance that the face can take on in people taking weight loss drugs. It can also increase signs of ageing – including lines, wrinkles and sagging skin.
This happens because the action of semaglutide (the active ingredient in both Ozempic and Wegovy) isn't localised to act just on the fat in places we don't want it. Instead, it acts on fat across the whole body – including in the face.
But it isn't just the appearance of your face that semaglutide affects. These drugs may also affect the mouth and teeth, too. And these side effects could potentially lead to lasting damage.
Semaglutide affects the salivary glands in the mouth. It does this by reducing saliva production (hyposalivation), which can in turn lead to dry mouth (xerostomia). This means there isn't enough saliva to keep the mouth wet.
It isn't exactly clear why semaglutide has this effect on the salivary glands. But in animal studies of the drug, it appears that the drug makes saliva stickier. This means there's less fluid to moisten the mouth, causing it to dry out.
GLP-1 receptor agonist drugs (such as semaglutide) can also reduce water intake by affecting areas in the brain responsible for thirst. Low fluid intake further reduces saliva production and may even cause the saliva to become thick and frothy and the tongue to become sticky.
One other commonly reported unwanted effect by semaglutide users is bad breath (halitosis).
When there's less saliva flowing through the mouth, this encourages bacteria that contribute to bad breath and the formation of cavities to thrive. These bacterial species include Streptococcus mutans and some strains of Lactobacillus.
Another species that has been shown to thrive in conditions where saliva is reduced is Porphyromonas gingivalis. This bacteria is a significant contributor to the production of volatile sulphur compounds, which cause the foul odours characteristic of halitosis.
Another factor that might explain why semaglutide causes bad breath is because less saliva being produced means the tongue isn't cleaned. This is the same reason why your 'morning breath' is so bad, because we naturally produce less saliva at night. This allows bacteria to grow and produce odours. Case report images show some people taking semaglutide have a 'furry'-like or coated appearance to their tongue. This indicates a buildup of bacteria that contribute to bad breath.
One of the major side effects of Ozempic is vomiting. Semaglutide slows how quickly the stomach empties, delaying digestion, which can lead to bloating, nausea and vomiting.
Repeated vomiting can damage the teeth. This is because stomach acid, composed primarily of hydrochloric acid, erodes the enamel of the teeth. Where vomiting occurs over a prolonged period of months and years, the more damage will occur. The back surface of the teeth (palatal surface) closest to the tongue are more likely to see damage – and this damage may not be obvious to the sufferer.
Vomiting also reduces the amount of fluid in the body. When combined with reduced saliva production, this puts the teeth at even greater risk of damage. This is because saliva helps neutralise the acid that causes dental damage.
Saliva also contributes to the dental pellicle – a thin, protective layer that the saliva forms on the surface of the teeth. It's thickest on the tongue-facing surface of the bottom row of teeth. In people who produce less saliva, the dental pellicle contains fewer mucins – a type of mucus which helps saliva stick to the teeth.
If you're taking semaglutide, there are many things you can do to keep your mouth healthy.
Drinking water regularly during the day can help keep the oral surfaces from drying out. This helps maintain your natural oral microbiome, which can reduce the risk of an overgrowth of the bacteria that cause bad breath and tooth damage.
Drinking plenty of water also enables the body to produce the saliva needed to prevent dry mouth, ideally the recommended daily amount of six to eight glasses. Chewing sugar-free gum is also a sensible option as it helps to encourage saliva production. Swallowing this saliva keeps the valuable fluid within the body. Gums containing eucalyptus may help to prevent halitosis, too.
There's some evidence that probiotics may help to alleviate bad breath, at least in the short term. Using probiotic supplements or consuming probiotic-rich foods (such as yoghurt or kefir) may be a good idea.
Practising good basic oral hygiene, tooth brushing, reducing acidic foods and sugary drinks and using a mouthwash all help to protect your teeth as well.
Women are twice as likely to have side effects when taking GLP-1 receptor agonists, including gastrointestinal symptoms such as vomiting. This may be due to the sex hormones oestrogen and progesterone, which can alter the gut's sensitivity. To avoid vomiting, try eating smaller meals since the stomach stays fuller for longer while taking semaglutide.
If you are sick, don't immediately brush your teeth as this will spread the stomach's acid over the surface of the teeth and increase the risk of damage. Instead, rinse your mouth out with water or mouthwash to reduce the strength of the acid and wait at least 30 minutes before brushing.
It isn't clear how long these side effects last; they'll likely disappear when the medication is stopped, but any damage to the teeth is permanent. Gastrointestinal side effects can last a few weeks but usually resolve on their own unless a higher dose is taken.
Adam Taylor is a Professor of Anatomy at Lancaster University.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
19 hours ago
- New York Post
Ozempic users aged backwards by more than 3 years in new trial
An astonishing new trial suggests that Ozempic may help users not only drop pounds but also turn back time. In the first trial to directly measure the impact of semaglutide on aging, half of the participants were given a weekly injection of Ozempic while the other half received a placebo for 32 weeks. 'Those on semaglutide drug became, on average, 3.1 years biologically younger by the end of the study,' diagnostic researcher Varun Dwaraka reported. The placebo group showed no significant change in biological age over the same period. Researchers believe these powerful anti-aging qualities are related to Ozempic's effect on fat distribution and metabolic health. millaf – While everyone knows their chronological age, medical experts often speak in terms of biological or 'phenotypic' age, which measures factors like metabolism, inflammation, and organ function. Researchers note that the anti-aging effects of GLP-1 varied across the body's systems. The most dramatic improvements were to the brain and inflammatory system, where the drug, originally developed to treat diabetes, appeared to delay biological aging by nearly 5 years. The teams also noted significant improvement in the heart and kidneys. 'The drug may not only slow the rate of aging, but in some individuals partially reverse it,' Dwaraka said. Researchers believe these powerful anti-aging qualities are related to Ozempic's effect on fat distribution and metabolic health. In essence, excess fat around the body's organs promotes the release of pro-aging molecules. Obesity causes low-grade chronic inflammation, which is when the body's natural chemical response to an irritant or injury remains active long after the threat has passed. GLP-1 drugs indirectly reduce inflammation through weight loss. The meds can also activate specific T cells — white blood cells key to the immune system — which can have anti-inflammatory effects. 'The drug may not only slow the rate of aging, but in some individuals partially reverse it,' a researcher on the study said. Ilzer/ – By reducing excess fat and inflammation, two hallmarks of epigenetic aging, the drug effectively slows the cruel march of deterioration. The use of GLP-1 medications has proliferated in recent years. A recent KFF health poll revealed that 12% of US adults have taken an Ozempic-like drug at some point. Despite the promising results, Dwaraka said caution and patience are called for. 'Prescribing it more broadly as an anti-ageing therapy is premature,' he said. However, he and his team are hopeful their research will inspire further studies and support the repurposing of existing drugs to treat age-related problems, as these established medications are more likely to be fast-tracked for approval and come without the risk of unforeseen side effects. 'Semaglutide may well emerge as one of the most promising candidates in this space,' Dwaraka concluded. GLP-1 drugs like Ozempic and Wegovy have been linked to a host of benefits beyond diabetes management and weight loss, from reduced dementia risk and decreased cancer risk to addiction treatment.
CNBC
2 days ago
- CNBC
From Starbucks to Smoothie King, restaurants seek to cash in on consumers' protein frenzy
Restaurant chains are joining in on the protein frenzy, hoping to encourage diners to pay more for extra macronutrients during a time when many consumers aren't spending as much. From "gym bros" to users of GLP-1 drugs like Ozempic, many Americans are trying to add more protein to their diets, with the goal of building or maintaining their muscle mass and feeling more satiated after meals. Moreover, diet trends that don't emphasize protein intake, such as the ketogenic diet, have fallen out of favor. "A lot of younger consumers are more proactive about their health habits, so they're looking for ways to support health now but also to support their health in the future," said Julia Mills, a food and drink analyst for market research firm Mintel. "Generation Alpha, Gen Z, millennials — these consumers are very active on social media, so they're constantly being fed this message that you need more protein, and protein helps you gain muscle and makes you stronger." Roughly a third of consumers said they loved high protein in the second quarter of 2025, up from 24% three years ago, according to Datassential, which tracks restaurant menus and consumer preferences. The trend has fueled a protein takeover in grocery store aisles, from protein-packed Eggo waffles to Khloe Kardashian's Khloud protein popcorn. But it's also hitting the menus of restaurants that are seeking ways to encourage diners to pay for premium food and drinks. Take Starbucks, for example. The coffee giant said in late July that it will roll out a cold foam packed with 15 grams of protein later this year; the regular cold foam add-on typically costs customers an extra $1.25 per drink. The new foam comes as the chain's U.S. sales have been shrinking for the past year as coffee drinkers brew their java at home or seek out trendier options. Rival Dutch Bros launched a protein coffee in early 2024 and charges customers an extra $1 for the customization. The menu addition fueled strong same-store sales growth and profits for the upstart chain. Eateries are seeking to attract diners like Jared Hutkowski, a 42-year-old director of brokerage in Harrisburg, Pennsylvania. He works out six days a week and tries to hit his daily protein goal to improve his physique and overall health. When he dines out, he tries to maximize his protein, although he sometimes goes for pizza anyway. "The biggest factor is what I am in the mood for that day, and then I normally try and select a meal that has a least a serving of some type of protein in it," Hutkowski said. This year, 28.4% of U.S. restaurant menus call out "protein," up from 5.9% a decade ago, according to Datassential. And the trend looks like it has staying power. Datassential predicts that by 2029, more than 40% of eateries will highlight protein on their menus. "Protein is one of those things that's never been vilified, because no one's ever said that eating too much protein can be bad for you," Mintel's Mills said. In the short term, consuming more protein than your body needs likely won't cause health issues, but in the long term, it could cause kidney problems, according to Diane Han, a registered dietitian based in San Francisco and the founder of Woking Balance Wellness. The recommended daily amount of protein intake varies by body weight but is roughly 46 grams for women and 56 grams for men, according to the Centers for Disease Control and Prevention. For restaurants, protein's step change happened several years ago. In 2021, protein only had a menu penetration of 11.5%; by 2022, more than a quarter of restaurant menus used the term, based on Datassential data. That year, Dine Brands' IHOP, for example, introduced pancakes with 18 grams of protein per flapjack. Fast-casual eateries are the restaurant segment most likely to call out protein on their menus, thanks to the common practice of asking customers to pick their protein or offering to double their portion, according to Datassential. Fast-casual salad chain Sweetgreen introduced a line of "protein plates" in late 2023 as part of an effort to introduce more hearty options for dinner customers. The menu addition has helped the company grow its dinner business from 35% of sales to about 40%, executives said in March. Many restaurants are also leaning into U.S. consumers' desire for convenience. Accessibility may be why Datassential found that consumers tend to prefer protein-packed beverages. For Smoothie King, protein has been a menu staple since its founding more than 50 years ago. But in October, the chain took one step further, launching a menu aimed at consumers who take GLP-1 drugs for weight loss or diabetes. The rapid weight loss that can occur from the medications can cause muscle mass to drop, so doctors often advise patients to increase their protein intake to maintain their muscle. "It's a convenient, on-the-go way to get in your protein that you're looking for in your diet," said Lori Primavera, Smoothie King's vice president of research and development and product marketing. Many restaurants are also choosing to highlight existing protein-packed options, rather than adding new menu items that would slow down kitchens or add to much complexity to their operations. For example, Panda Express introduced its own protein plates earlier this year. The line, created in partnership with a registered dietitian, includes pre-existing menu items but packages them as a balanced meal, highlighting protein and fiber content. Chipotle Mexican Grill employed a similar strategy back in 2019 when it introduced "lifestyle bowls," marketed to fit different dietary goals, like the paleo diet or offering double protein. Likewise, in July, Chick-fil-A put the spotlight on its own high-protein options in a company blog, highlighting its grilled nuggets and the Cool Wrap, which features a grilled chicken breast, cheese and lettuce in a tortilla. But for the eateries that want to add new menu items, nachos with a choice of protein, restaurant-made protein bars and egg dishes that highlight high protein content are all increasingly popular options, according to Datassential trendologist Claire Conaghan. Eggs are one reason why breakfast, brunch and lunch eatery First Watch has always been "protein forward," CEO Chris Tomasso told CNBC. The chain hasn't adjusted its menu specifically to address consumers' demand for more protein, but TikTok influencers have highlighted how to order a high-protein meal when visiting its restaurants. "We hope that continues to be a trend because we're right down the middle of the fairway on that," Tomasso said. Of course, protein isn't the only way to win over health-conscious consumers. Hutkowski said his primary issue with eating at restaurants is that most of the food is cooked in oils, butter and heavy greases that rapidly add to his intake of fats for the day. "A restaurant finding cleaner ways to cook would be much more attractive to me than overly loaded protein dishes," he said.
Business Insider
2 days ago
- Business Insider
Sector Spotlight: Trump administration seeks hometown discount from Big Pharma
Welcome to the latest 'Sector Spotlight,' where The Fly looks at a new industry every week and highlights its happenings. This edition focuses on the pharmaceutical sector following a busy week of earnings and political news. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. PHARMACEUTICAL NEWS: The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, Reuters' Patrick Wingrove and Maggie Fick reported, citing a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries. President Donald Trump said while being interviewed on CNBC earlier this week that separate tariff announcements are coming soon on semiconductor chips and pharmaceuticals. GSK (GSK) announced that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech (BNTX) on, the company will receive an upfront settlement of $370M. GSK will also receive a 1% royalty in respect of US sales of influenza, COVID-19 and related combination mRNA vaccine products by BioNTech and Pfizer (PFE) from the beginning of 2025. These payments are due to GSK in accordance with the terms of its existing license agreement with CureVac. Of the upfront settlement amount, $320m will be in cash. The remainder is attributed to the value of an amendment to GSK's existing agreement with CureVac, which includes a significant reduction in royalties to be paid by GSK on our potential future mRNA influenza, COVID-19 and influenza/COVID-19 combination products. If the pending acquisition of CureVac by BioNTech successfully closes, the mRNA patent litigation between CureVac and BioNTech outside of the US will also be settled. GSK would then be entitled to an additional $130 million in cash and 1% royalty payments in respect of future sales outside of the US by BioNTech and Pfizer. Sales of Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Mounjaro doubled in India in July compared to June, Rishika Sadam and Kashish Tandon of Reuters noted, citing research firm Pharmarack. Demand for anti-obesity drugs has been on an upswing in the country. Novartis (NVS) has made a takeover offer for Avidity Biosciences (RNA), which has a market value of $4.3B, The Financial Times' Oliver Barnes, James Fontanella-Khan and Hannah Kuchler wrote. Avidity, which has three medicines in clinical trials that treat different forms of muscular dystrophy, is working with advisers to assess its options, people familiar with the matter say. The U.S. Department of Health and Human Services announced the beginning of a coordinated wind-down of its mRNA vaccine development activities under the Biomedical Advanced Research and Development Authority, including the cancellation and de-scoping of various contracts and solicitations. The decision follows a comprehensive review of mRNA-related investments initiated during the COVID-19 public health emergency. 'We reviewed the science, listened to the experts, and acted,' said HHS Secretary Robert F. Kennedy, Jr. 'BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate.' The wind-down affects a range of programs including: Cancellation of BARDA's award to Moderna (MRNA) /UTMB for an mRNA-based H5N1 vaccine; Termination of contracts with Emory University and Tiba Biotech; De-scoping of mRNA-related work in existing contracts with Luminary Labs, ModeX, and Seqirus; Rejection or cancellation of multiple pre-award solicitations, including proposals from Pfizer , Sanofi Pasteur (SNY), CSL Seqirus, Gritstone, and others, as part of BARDA's Rapid Response Partnership Vehicle and VITAL Hub, and; Restructuring of collaborations with DoD-JPEO, affecting nucleic acid-based vaccine projects with AAHI, AstraZeneca (AZN), and HDT Bio. Bristol Myers (BMY) announced that the FDA has accepted the supplemental biologics license application for Breyanzi as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior lines of systemic therapy. EARNINGS RECAP: Eli Lilly's second quarter results beat expectations and the company raised its full-year outlook as well. However, shares of the company were down 7% on Thursday morning after the company reported data from a late-stage trial of its under-development obesity pill. 'Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines,' said David Ricks, Lilly chair and CEO. 'Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health-including Mounjaro's demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and strong data for our oral incretin, orforglipron, in obesity. We also expanded manufacturing capacity to meet increasing demand and invested in key R&D initiatives to support our long-term growth.' Leerink downgraded Eli Lilly to Market Perform from Outperform with a price target of $715, down from $944. Following 'disappointing' initial results for orforglipron, the company's oral GLP-1, the firm is lowering its long-term projections and notes that its 'investment thesis has changed' as it no longer expects upward pressure on long-term consensus expectations. The firm also noted that Lilly's major competitor Novo Nordisk is struggling and may need to continue to use price to compete in its duopoly while the firm expects growing competition from various competitors starting late decade. Conversely, JPMorgan views the post-earnings selloff in shares of Eli Lilly as providing a 'compelling' entry point. The Q2 report came in well ahead of consensus estimates and Lilly is raised guidance, which should dispel some weight loss market concerns, the analyst tells investors. However, the firm says the bigger focus was on orforglipron's Phase 3 obesity data where weight loss came in slightly below expectations. JPMorgan does not see 1-2 percentage points lower weight loss as meaningfully changing the use case for orforglipron. It keeps an Overweight rating on Lilly shares with a $1,100 price target. Pfizer also experienced a beat and raise quarter in Q2. Although, the company did note that its FY25 guidance does not anticipate any share repurchases. On the company's Q2 earning call, Pfizer noted that the company's guidance 'absorbs the impact of the currently imposed tariffs from China, Canada and Mexico as well as potential price changes this year based on the letter received on July 31 from President Trump.' Later in the call, Pfizer CEO Albert Bourla said the company is 'in very active discussions' at 'the highest levels of this government.' Bourla added: 'I discussed myself with the president after he sent the letter to me and all the others. We discussed a lot with the Secretary Kennedy, we discussed a lot with Doctor Post who is responsible for implementing a lot of these things. And I would say only that these discussions are extremely productive. I think we understand where the president comes from, and we are engaging in a productive way to find a solution. But because we are in active discussions, it's inappropriate for me to start providing more details because I don't want to say things while discussing with them. So I understand that many others may have questions about that, and I'm not sure I can give more information than what I just told you. That we had a letter that says a base of what the president wants. The letter asks a lot from us. But we are engaged in productive discussions with them.' Following the report, Citi analyst Geoff Meacham raised the firm's price target on Pfizer to $26 from $25 and reiterated a Neutral rating on the shares. The company reported strong Q2 results, but policy headwinds warrant a continued cautious stance, the analyst told investors.
